Oxford Nanopore Technologies Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Oxford Nanopore Technologies şirketinin kazançları yıllık ortalama -16.9% oranında azalırken, Life Sciences sektörünün kazançları yıllık 13.9% oranında artan oldu. Gelirler yıllık ortalama 6.8% oranında artan oldu.

Anahtar bilgiler

-16.9%

Kazanç büyüme oranı

-12.3%

EPS büyüme oranı

Life Sciences Sektör Büyümesi	26.8%
Gelir büyüme oranı	6.8%
Özkaynak getirisi	-27.5%
Net Marj	-94.8%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Oxford Nanopore Technologies nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:4R0 Gelir, gider ve kazançlar (GBP Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	168	-159	154	102
31 Mar 24	169	-157	154	103
31 Dec 23	170	-155	155	103
30 Sep 23	166	-143	156	95
30 Jun 23	162	-131	157	88
31 Mar 23	180	-111	149	74
31 Dec 22	199	-91	141	59
30 Sep 22	198	-122	160	62
30 Jun 22	197	-153	179	65
31 Mar 22	165	-160	170	70
31 Dec 21	134	-168	162	76
30 Sep 21	129	-119	121	66
30 Jun 21	125	-71	80	55
31 Mar 21	119	-66	76	52
31 Dec 20	114	-61	71	49
31 Dec 19	52	-72	66	40
31 Dec 18	33	-53	42	37
31 Dec 17	14	-57	38	35
31 Dec 16	5	-59	26	38
31 Dec 15	1	-39	17	27
31 Dec 14	0	-37	13	28

Kaliteli Kazançlar: 4R0 şu anda kârlı değil.

Büyüyen Kar Marjı: 4R0 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 4R0 kârlı değildir ve zararlar son 5 yılda yılda 16.9% oranında artmıştır.

Büyüme Hızlandırma: 4R0 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 4R0 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Life Sciences sektörüyle ( 5.4% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 4R0 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -27.49% ) sahiptir.

Oxford Nanopore Technologies Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First half 2024 earnings released: UK£0.087 loss per share (vs UK£0.085 loss in 1H 2023)

Oxford Nanopore Technologies plc to Report First Half, 2024 Results on Sep 03, 2024

Full year 2023 earnings released: UK£0.19 loss per share (vs UK£0.11 loss in FY 2022)

Oxford Nanopore Technologies plc to Report Fiscal Year 2023 Results on Mar 06, 2024

First half 2023 earnings released: UK£0.085 loss per share (vs UK£0.037 loss in 1H 2022)

Oxford Nanopore Technologies plc to Report First Half, 2023 Results on Sep 06, 2023

Recent updates

Oxford Nanopore Technologies plc Announces Executive Changes

Co-Founder recently sold €3.4m worth of stock

Oxford Nanopore Technologies plc Appoints Daniel Mahony as A Non-Executive Director

First half 2024 earnings released: UK£0.087 loss per share (vs UK£0.085 loss in 1H 2023)

New major risk - Share price stability

Oxford Nanopore Technologies plc announced that it expects to receive £50 million in funding from Novo Holdings

Oxford Nanopore Technologies plc Announces Changes to Director

Oxford Nanopore Technologies plc Provides Updates to its Clinical Product Pipeline

Oxford Nanopore Technologies plc to Report First Half, 2024 Results on Sep 03, 2024

Oxford Nanopore Technologies plc, Annual General Meeting, Jun 10, 2024

Non-Executive Chair recently bought €348k worth of stock

Oxford Nanopore Technologies plc Provides Earnings Guidance for the Year 2024

Oxford Nanopore Technologies Launches PromethION 2 Integrated into Open Early Access

Full year 2023 earnings released: UK£0.19 loss per share (vs UK£0.11 loss in FY 2022)

New major risk - Revenue and earnings growth

Oxford Nanopore Technologies plc Announces Directorate Change

Oxford Nanopore Technologies plc Announces CFO Changes

Oxford Nanopore Technologies plc Provides Earnings Guidance for the Year 2023

Oxford Nanopore Technologies plc to Report Fiscal Year 2023 Results on Mar 06, 2024

Oxford Nanopore Technologies plc Announces Board Changes

New minor risk - Shareholder dilution

First half 2023 earnings released: UK£0.085 loss per share (vs UK£0.037 loss in 1H 2022)

Oxford Nanopore Technologies Launches Pilot Accessible Sequencing Education Programme

Less than half of directors are independent

Oxford Nanopore Technologies plc to Report First Half, 2023 Results on Sep 06, 2023

Oxford Nanopore Technologies plc Appoints Kate Priestman as Non-Executive Director

Non-Executive Chair recently bought €246k worth of stock

Full year 2022 earnings released: UK£0.11 loss per share (vs UK£0.23 loss in FY 2021)

Oxford Nanopore Technologies plc to Report Fiscal Year 2022 Results on Mar 21, 2023

CTO & Director recently sold €1.1m worth of stock

Less than half of directors are independent

First half 2022 earnings released: EPS: UK£0 (vs UK£0 in 1H 2021)

Oxford Nanopore Technologies plc to Report First Half, 2022 Results on Sep 13, 2022

Less than half of directors are independent

Oxford Nanopore Technologies plc Appoints Duncan Tatton-Brown as Non-Executive Chair

Oxford Nanopore Technologies plc Appoints Duncan Tatton-Brown as Non-Executive Chair with Effect from 1 August 2022

Insider recently bought €58k worth of stock

Oxford Nanopore Delivers Technology Update At Annual London Calling Conference: Bringing Together Years of Innovation to Showcase One Sensing Platform for All Biological Analyses

Less than half of directors are independent

Oxford Nanopore Technologies Limited, Annual General Meeting, Jun 23, 2022

Oxford Nanopore Technologies Limited to Report Fiscal Year 2021 Results on Mar 22, 2022

Oxford Nanopore Technologies plc Provides Revenue Guidance for the Fiscal Year Ended 31 December 2021

Oxford Nanopore Announces Technology Updates

No independent directors

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin